https://www.fiercebiotech.com/biotech/merck-stops-phase-3-tigit-trial-lung-cancer-futility-and-sees-immune-side-effects-again
efti looking more like a target for Merck. I believe IMMP also holds a patent for use with ANY PD-1 blocker, which would include generic keytruda when its patent runs out soon for Merck. OS data from HNSC out later this year will back up the possibility of PH3 success in lung.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $344.9M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $419.6K | 1.793M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191371 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 116318 | 2 |
View Market Depth
| Last trade - 16.10pm 10/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |